background image
showed that aspirin reduced mortality.
e ndings of the study transformed
preventative heart-attack treatment on
a worldwide scale.
"I have been involved in acute
myocardial infarction (AMI) research
since completing the ISIS-2 trial.
When I came to the US in 1987, these
large-scale trials were not operational,
so I became a steering committee
member, and regional coordinator
in the southeast region, for the
Global Utilisation of Streptokinase
and tPA for Occluded Coronary
Arteries (GUSTO-1) trial, a follow-
up study. It was a rst in the US, with
41,000 patients enrolled the largest
cardiological trial ever completed."
is set the stage for the research that
Professor Ohman has been doing ever
since. Now, on the other side of the
spectrum, he is working on trying to
remove aspirin from use in heart-attack
treatment. e trials are due to go into
phase III next year. "My career began
with aspirin and now I am seeking to
remove aspirin, years later. Science
moves forward, it never stands still."
Professor Ohman says that the values
and the approaches that health
professionals take change all the time.
Because, he says, he is continually
doing collaborative research, this
leads to lots of publications. He
credits these collaborations for his
recognition in the omson Reuters
listing, which measures the number
of citations of your papers in top
journals. " e World's Most In uential
Scienti c Minds" listing is a citation
analysis identifying the scientists as
determined by their fellow researchers
who have made the most signi cant
global impact within their respective
eld of study. "It is unique that my
former colleague and RCSI peer,
Professor Koon Teo (Medicine, Class of
1978) I call him KK was also on the
omson Reuters list this year and also
worked under Professor Horgan. It is
a measure of how in uential Professor
Horgan has been on the RCSI Alumni
in our eld. His role as a mentor in my
life has led me to try and achieve the
same status in the US."
Over the past 10 years, Professor
Ohman has set up a mentoring
programme at Duke Medical Institute,
where he mentors junior and mid-level
physicians Assistant and Associate
Professors on their research. "I was
fortunate at College, with lecturers who
genuinely had a vested interest in my
future career. So, I would like to think
that in the future, my own students will
appreciate me as I appreciate my former
lecturers at RCSI."
"Science moves forward, it never stands still...
the values and the approaches that
health professionals take change all the time."
Professor Ohman with his mother, Maj-Britt Borjeson, wife, Elspeth and his children, Henry,
Edward and Elsa, during their visit to RCSI in November 2015.
RCSI is leading a major
international research programme
to develop regenerative therapies
for the repair of damaged heart
tissue caused by heart attacks.
e Advanced Materials
for Cardiac Regeneration
(AMCARE) programme is
carrying out research to develop
natural materials and new
surgical devices to enhance the
delivery of the body's own stem
cells to the heart to promote
healing a er a heart attack
(myocardial infarction) and
prevent premature death.
e therapies being developed
will replace heart cells, which die
due to the reduced blood ow
that occurs during a heart attack,
with new, healthy cells derived
from stem cells that come from
the patient's own bone marrow.
AMCARE is coordinated by
Dr Garry Du y, Department
of Anatomy and Tissue
Engineering Research Group,
RCSI and AMBER Investigator:
"Regenerative therapies have the
potential to revolutionise the
treatment of patients who have
su ered a heart attack. We hope
to reduce the need for highly
invasive surgical procedures
with extensive patient recovery
times by developing alternative,
minimally invasive biomaterial
therapies that will use custom
medical devices to access the
heart, while ensuring the best
outcomes for patients."
Find out more at
On average, 17.5
million people
die each year
from CVDs
(Source: WHO)
RCSI MattersSRH.indd 29
03/03/2016 11:54